REGENXBIO Inc. Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross
REGENXBIO Inc. (RGNX) had Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross of $101.00 thousand as of 2018-12-31, per its 10-K filed 2020-02-26.
Discontinued › Notes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross · last filed 2020-02-26
- 2018-12-31: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $101.00K.
- 2017-12-31: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $89.00K.
- 2015-12-31: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $284.00K.
| Period end | Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross |
|---|---|
| 2018-12-31 | $101.00K 10-K · filed 2020-02-26 |
| 2017-12-31 | $89.00K 10-K · filed 2019-02-27 |
| 2015-12-31 | $284.00K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |